Evidence map›Paper›PMID 19250532›Full record

ReviewJournal of hematology & oncology2009

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.

Brady Beltran, Jorge Castillo, Renzo Salas, Pilar Quiñones, Domingo Morales, Fernando Hurtado, Luis Riva, Eric Winer

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Hematolymphoid lesions of the sinonasal tract.Seminars in diagnostic pathology · 2016
    Review
  16. Article
  17. Review
  18. Article
  19. ALK-driven tumors and targeted therapy: focus on crizotinib.Pharmacogenomics and personalized medicine · 2014
    Review
  20. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brady BeltranDepartment of Oncology and Radiotherapy, Edgardo Rebagliati Martins Hospital, Lima, Peru. bgbrady@hotmail.com
Jorge Castillo
Renzo Salas
Pilar Quiñones
Domingo Morales
Fernando Hurtado
Luis Riva
Eric Winer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL). The latest WHO classification of lymphomas recognizes ALK-DLBCL as a separate entity.

methodsA comprehensive comparison was made between the clinical and pathological features of the 4 cases reported and those found in an extensive literature search using MEDLINE through December 2008.

resultsIn our series, three cases were adults and one was pediatric. Two cases had primary extranodal disease (multifocal bone and right nasal fossa). Stages were I (n = 1), II (n = 1), III (n = 1) and IV (n = 1). Two cases had increased LDH levels and three reported B symptoms. IPI scores were 0 (n = 1), 2 (n = 2) and 3 (n = 1). All cases exhibited plasmablastic morphology. By immunohistochemistry, cases were positive for cytoplasmic ALK, MUM1, CD45, and EMA; they marked negative for CD3, CD30 and CD20. Studies for EBV and HHV-8 were negative. The survival for the patients with stage I, II, III and IV were 13, 62, 72 and 11 months, respectively.

conclusionALK-DLBCL is a distinct variant of DLBCL with plasmacytic differentiation, which is characterized by a bimodal age incidence curve, primarily nodal involvement, plasmablastic morphology, lack of expression of CD20, aggressive behavior and poor response to standard therapies, although some cases can have prolonged survival as the cases reported in this study. ALK-DLBCL does not seem associated to immunosuppression or the presence of EBV or HHV8. Further prospective studies are needed to optimize therapies for this entity.

Indexed as

AdolescentAdultAgedAnaplastic Lymphoma KinaseAntigens, CD20FemaleHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsLymphoma, Large B-Cell, DiffuseMalePrognosisProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesALK protein, humanAnaplastic Lymphoma KinaseAntigens, CD20Interferon Regulatory Factor-4Interferon Regulatory FactorsProtein-Tyrosine KinasesReceptor Protein-Tyrosine Kinases

Identifiers

PMID19250532
PMCPMC2651189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.